Parthenogenesis-derived multipotent stem cells adapted for tissue engineering applications.
Embryonic stem cells are envisioned as a viable source of pluripotent cells for use in regenerative medicine applications when donor tissue is not available. However, most current harvest techniques for embryonic stem cells require the destruction of embryos, which has led to significant political and ethical limitations on their usage. Parthenogenesis, the process by which an egg can develop into an embryo in the absence of sperm, may be a potential source of embryonic stem cells that may avoid some of the political and ethical concerns surrounding embryonic stem cells. Here we provide the technical aspects of embryonic stem cell isolation and expansion from the parthenogenetic activation of oocytes. These cells were characterized for their stem-cell properties. In addition, these cells were induced to differentiate to the myogenic, osteogenic, adipogenic, and endothelial lineages, and were able to form muscle-like and bony-like tissue in vivo. Furthermore, parthenogenetic stem cells were able to integrate into injured muscle tissue. Together, these results demonstrate that parthenogenetic stem cells can be successfully isolated and utilized for various tissue engineering applications.
Koh
Chester J
CJ
Wake Forest Institute for Regenerative Medicine, Winston Salem, NC 27157, USA. ckoh@chla.usc.edu
Delo
Dawn M
DM
Lee
Jang Won
JW
Siddiqui
M Minhaj
MM
Lanza
Robert P
RP
Soker
Shay
S
Yoo
James J
JJ
Atala
Anthony
A
D000818:Animals; D002454:Cell Differentiation; D004558:Electric Stimulation; D051379:Mice; D039902:Multipotent Stem Cells / Q000502:physiology*; D009865:Oocytes / Q000502:physiology*; D010312:Parthenogenesis; D011817:Rabbits; D023822:Tissue Engineering / Q000379:methods*
Mol Med. 2000 Feb;6(2):88-95
10859025
Nature. 2008 Jan 10;451(7175):141-6
18157115
Nat Biotechnol. 2007 Oct;25(10):1177-81
17724450
Science. 2002 Feb 1;295(5556):819
11823632
Science. 2003 May 9;300(5621):913-6
12738841
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10716-21
11535826
Nat Biotechnol. 2007 Jan;25(1):100-6
17206138
J Cell Biochem. 1997 Feb;64(2):295-312
9027589
Science. 2001 Aug 17;293(5533):1242-5
11509703
In Vitro Cell Dev Biol Anim. 1995 Nov;31(10):773-9
8564066
N Engl J Med. 2004 Mar 25;350(13):1353-6
14999088
Exp Cell Res. 2006 Nov 1;312(18):3669-82
16996056
Cell Prolif. 2008 Feb;41 Suppl 1:20-30
18181942
Stem Cells. 2008 Mar;26(3):756-66
18192229
Cell Res. 2008 Feb;18(2):215-7
18246085
Nat Biotechnol. 2001 Dec;19(12):1134-40
11731782
Nature. 1977 Jan 6;265(5589):53-5
556803
Mol Reprod Dev. 2007 Oct;74(10):1295-302
17290421
Nat Biotechnol. 2001 Dec;19(12):1129-33
11731781
Cell. 1984 May;37(1):179-83
6722870
Tissue Eng. 2003 Apr;9(2):301-6
12740092
Cell Res. 2007 Dec;17(12):1008-19
18071366
Science. 2008 Feb 1;319(5863):560-3
18239100
Mol Reprod Dev. 1992 Nov;33(3):357-62
1449802
J Clin Invest. 2001 Aug;108(3):407-14
11489934
J Cell Biol. 1995 Sep;130(6):1461-72
7559766
Cell Res. 2007 Dec;17(12):999-1007
18040289
Nature. 2004 Apr 22;428(6985):860-4
15103378
Science. 1998 Mar 6;279(5356):1528-30
9488650
Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11911-6
14504386
Cell. 2007 Nov 30;131(5):861-72
18035408
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11307-12
11027332
Science. 2003 May 9;300(5621):865
12738815
Nat Biotechnol. 1999 Feb;17(2):149-55
10052350
Diabetes. 2001 Aug;50(8):1691-7
11473026
Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4391-6
11917100
Brain Res. 2001 Sep 21;913(2):201-5
11549388
Birth Defects Res A Clin Mol Teratol. 2004 Jan;70(1):40-6
14745894
J Urol. 2002 Oct;168(4 Pt 2):1789-92; discussion 1792-3
12352360